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ABSTRACT 
In parallel to monomeric epigenetic regulators, sequence-specific epigenetic regulators represent 
versatile synthetic dual-function ligands that achieve regulatory control over multi-gene networks. 
DNA-binding domain (DBD)-HDAC inhibitors and DBD-HAT activators, which result in 
increased histone acetylation, have become one promising research field. However, there is no 
report of the gene regulatory pattern of sequence-specific epigenetic repressors. We report here the 
synthesis of DBD-HAT inhibitors and the evaluation of their antitumor activity in cancer cells. 
Among all synthesized compounds, 2 (with a medium linker length of 13-atom) exhibited the 
highest antitumor activity, with an IC50 of 1.8 µM, in A549 cells, whereas HAT inhibitor 
monomers showed no antiproliferative activity. In addition, we used Microarray experiment and 
an apoptotic assay to show that the antitumor mechanisms of 2 occurred via the regulation of p53 
target genes and triggered subsequent p53-dependent apoptosis 
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Among epigenetic families, histone acetylation has been identified as a key histone marker that 
switches on gene expression. Moreover, its dysregulation might cause the development of 
substantial diseases [1]. Dozens of epigenetic agents, such as histone deacetylase (HDAC) 
inhibitors (SAHA and TSA), histone acetyltransferase ( HAT) activators (CTB and CTPB) and 
HAT inhibitors (C646 and anacardic acid), have been approved or are in preclinical development 
and show promising therapeutic efficacy [2-4]. In parallel to monomeric epigenetic regulators, 
sequence-specific epigenetic regulators have recently gained prominence as an emerging class of 
versatile synthetic dual-function ligands that achieve regulatory control over multi-gene networks 
(Figure 1) [5, 6].  
 
Figure 1. Chemical structures of the HDAC inhibitors SAHA and SAHA-I, HAT activators CTB and CTB-I, and 
HAT inhibitor C646. 
 
Our lab has focused on sequence-specific epigenetic regulators that involve conjugation with 
DNA-binding domains (DBDs) and pyrrole-imidazole polyamides (PIPs) [7]. PIPs are  
programmable DNA minor groove binders with the ability to recognize and bind specific DNA 
sequences strongly (with the Py/Py pair recognizing A/T or T/A, Py/Im recognizing C/G, and 
Im/Py recognizing G/C) [8]. By incorporating a variable 8-ring PIP moiety, a compound library of 
both HDAC inhibitor conjugates (SAHA-PIP) [9] and HAT activator conjugates (CTB-PIP) was 
constructed and showed accumulated histone acetylation, thereby being followed by downstream 
gene activation in living cells. Promisingly, after conjugation with SAHA, the PIP-I sequence 
(DNA-binding sequence, 5′–WWCCWW–3′, W = A/T) exhibited the highest potential to 
upregulate SOX2, OCT4 and NANOG, which are responsible for iPS cell formation and 
maintenance (Figure 1) [10]. More interestingly, when SAHA was replaced with CTB, CTB-I 
showed a gene activation pattern that was similar to that of SAHA-I, although it targeted a 
different epigenetic regulator [11].  
In contrast with SAHA and CTB, which functionally result in gene activation; however, no 
sequence-specific HAT inhibitor has been reported. In this work, we were interested in dual-
functional sequence-specific HAT inhibitors via C646 conjugation of PIP-I, for the development 
of novel cancer therapies [12]. Using our lab’s platform, an in vitro HAT activity assay showed a 
similar HAT inhibitory pattern between sequence-specific HAT inhibitors and monomeric HAT 
inhibitors. In addition, a cell viability assay showed that 2 (which contains PIP-I sequence and a 
medium length linker) had an IC50 of 1.8 µM in A549 cells. Moreover, a microarray analysis and 
an apoptotic assay revealed that upregulation of p53 target genes and apoptosis were responsible 
for the antitumor effect of 2. 
 
2. Results and discussion 
2.1 Design and synthesis 
C646, which was reported by Philip A. Cole through silica screening, is the most potent HAT 
inhibitor available currently. C646 inhibits p300 with a Ki value of 400 nM in vitro and 
significantly downregulates histone acetylation in human lung cancer cells and melanoma cells 
[12]. C646 contains a carboxyl group and its amide analogs or propargylamine conjugates exhibit 
the same level of HAT inhibitory activity, which implies that PIP conjugation at the carboxyl site 
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Scheme 1. Structural design of PIP conjugates of the HAT inhibitor C646 (C646-PIP).  
 
Inspired by the 8-ring PIP-I, we moved forward to PIP-I conjugation with the HAT inhibitor 
C646 (C646-I) [11].The linker region between the functional group and PIP might affect its 
binding affinity and functional effect. Our group reported six kinds of linkers of SAHA-PIP and 
revealed that a linker length of 12-atom yielded maximum expression of OCT3/4[14]. In this 
work, after taking linker length and chain flexibility into consideration, we designed C646-PIP-I 
conjugates with three types of linkers, i.e., a shorter linker (8-atom, 1), a moderate linker (13-
atom, 2) and a longer linker (18-atom, 3) (Scheme 1). Concomitantly, an alternative PIP sequence 
ligated with C646 (4) was also designed, to investigate the PIP sequence/activity relationship.  
C646-PIP synthesis started from pyrrole-oxime resin [15]. Using an 11-step Fmoc-protected solid-
phase synthesis, four conjugates were synthesized and cleaved by N,N-dimethylamine. After 
purification using a reverse-phase flash column, our target compounds were synthesized by 
combining the terminal amino group of the PIP chain with commercially available C646, which 
contains a carboxyl group, with the help of the coupling agent PyBOP. The compounds were then 
purified in high yield.  
 
2.2 In vitro HAT activity assay  
After conjugation with PIP, functional moieties, such as SAHA, CTB, and alkylating agents, still 
harbor their functional activity toward the primary targets, with only a slight loss of activity [16]. 
Therefore, it is mandatory that the conjugation of PIP-I with C646 does not diminish the histone 
acetylation inhibitory activity. We first evaluated the HAT activity of all synthesized C646-PIP 
conjugates using a commercially available HAT activity kit. We used p300 as the HAT enzyme, as 
C646 showed high selectivity to p300 compared with a panel of similar functional enzymes, such 
as PCAF, GCN5, AANAT, Sas, Moz, and Rtt109 [12]. The HAT inhibitory activity was assessed 
using fluorescence absorption on a microreader using the H3 peptide and Ac-CoA as substrates.  
 
 
Figure 2. HAT inhibitory activity assay. The enzymatic activity of HAT was tested in the presence of C646, 1, 2, 3, 
4, and PIP-I. Each effector was individually administered at two concentrations (1 and 5 µM) to the p300 enzyme 
using a HeLa cell nuclear extract as a positive control and the 0.5% DMSO group as a control group (100%). P < 
0.05. 
 
Our results showed an IC50 of 2.4 µM for C646, which is consistent with that reported previously. 
As expectedly, the PIP-I sequence without C646 did not possess HAT inhibitory activity. 
Concomitantly, all C646-PIP derivatives, regardless of linker region and PIP sequence, maintained 
HAT inhibitory activity, with IC50 values around 3.9–4.2 µM, which proved that C646-PIP 
preserved p300 inhibitory activity and the changes in PIP sequence had no obvious deleterious 
effects on IC50. In addition, the inhibitory activity of C646-PIP was slightly decreased compared 
with the C646 monomer, which might be explained by the fact that the PIP moiety constrains 
C646 binding to HAT, to a certain extent.  
 
2.3 Antitumor activity assay 
HAT inhibitors were studied in cancer cell lines in previous reports [3, 17]. After a 10-day 
treatment, C646 exhibited an IC50 of 10.0, 6.0, and 6.3 µM in A549, H157, and H460 cells, 
respectively, as assessed by a clonogenic survival assay based on a published article [18]. Under 
ionizing radiation therapy, C646 radiosensitized lung cancer cells by enhancing the mitotic 
catastrophe. However, those authors could only observe a limited dose ratio enhancement of 1.2–
1.4 fold, which implies that an alternative molecular design should be introduced.   
 
Figure 3. Cell viability assay in the A549 cell line using the WST-8 method. A549 cells were grown in 10% 
FBS/DMEM medium for 24 h. Subsequently, the medium was replenished with varying concentrations of C646-
PIP conjugates (0.1, 1, 5, and 10 µM) for 96 h. The cell viability of A549 cells was measured using the WST-8 
method. Each bar represents the mean ± SD from three wells. P < 0.05. 
 
Here, we studied the antitumor activity of C646-PIP using a cell viability assay in A549 cells [19]. 
As expectedly, A549 cell viability was almost not affected by PIP-I and C646, even at the 
concentration of 10 µM, after 96 h of treatment (Figure 3). Treatment with C646-PIP conjugates 
led to cell inhibition, , but the extent of activity varied considerably among conjugates with 
different linker lengths and PIP sequences.  
 
Regarding the shared PIP-I sequence, 2 (moderate linker with a 13-atom distance) exhibited the 
highest antitumor activity, with an IC50 of 1.8 µM, in a dose-dependent manner. This implies that 
the length of the linker played a pivotal role regarding its cellular effect, which was different from 
the simplified HAT inhibitory activity in vitro. If the linker length was too short (1), C646 was not 
sufficiently free to bind to the active pocket of p300 while PIP bound to DNA. In contrast, a linker 
that was too long (3) drove C646 out of the localized region of PIP binding, without sequence-
specificity. 2 and 4 had the same linker length (13-atom distance), but different PIP sequences. 
However, 4 showed only a slight antitumor activity in A549 cells, which implies that the PIP-I 
sequence is necessary for antitumor activity.  
We also tested 2 and 4 in SW620 cells, which contained mutant p53 (A549 cells contained wild-
type p53) (Supplementary Data S3). Our results showed that 2 had less activity in SW620 cells 
(IC50, 7.5 µM) compared with that observed in A549 cells (IC50, 1.85 µM).  
 
2.4 Microarray analysis 
Microarray analysis has been used widely to identify underlying regulatory gene patterns [20].  In 
this work, whole-genome transcriptional profiling of the A549 cell line was performed  using 
microarray analysis, according to the manufacturer’s protocol [21]. 2 (2 µM) and 4 (2 µM) were 
added respectively, for 48 h. 4 did not exhibit a specific gene regulatory pattern, which was 
consistent with its low antitumor activity. Regarding treatment with 2, among  the more than 
50,000 transcripts identified, 310 target genes showed 1.5-fold changes in expression levels (P < 
0.05), with upregulation observed for 170 transcripts and downregulation detected for 140 
transcripts. Genes detail information of microarray data up- and downregulated by treatment with 
2 with levels >1.8-fold and <–1.8-fold changes (p<0.05) by Affymetrix gene expression console 
software (Table 1). 
 
Table 1 Genes detail information of microarray data up- and downregulated by treatment with 2. Genes with >1.8-
fold and <–1.8-fold changes (P < 0.05). Uncharacterized transcripts were excluded from this table. Gene symbols 
in red color and green color are upregulated and downregulated p53 downstream targets, respectively. 
Gene Symbol Fold Change Gene Symbol Fold Change 
SPATA18 2.98  TP53INP1 1.85  
EDA2R 2.53  CD70 1.83  
ABCA12 2.42  FAS 1.83  
BTG2 2.35  GDF15 1.81  
MIR3189 2.32  GAS6-AS1 1.81  
CDKN1A 2.28  ANKRD1 1.81  
SULF2 2.13  DDB2 1.80  
WDR63 2.03  NEFL 1.80  
FDXR 2.00  SNORA9 -1.81  
MDM2 1.97  ALDH1L2 -1.86  
UIMC1 1.94  CARS -1.90  
MIR4713 1.94  ASNS -2.01  
SESN1 1.91  TAS2R30 -2.01  
SCARNA7 1.89  STC2 -2.34  
MIR3685 1.89  ULBP1 -2.34  
CYFIP2 1.88  GUSBP3 -2.63  
POLH 1.88  CHAC1 -3.64  
 
We performed an Ingenuity Pathway Analysis (IPA) of the differentially expressed genes, to gain a 
more precise global understanding of the underlying biological processes (Figure 4a) [22]. 
Interestingly, while 4 did not show potent and specific gene pattern regulations, treatment with 2 
led to a strong enrichment of p53 target genes, such as SPATA18 (2.98 fold), BTG2 (2.35 fold), 
FDXR (2.00 fold), and MDM2 (1.97 fold),  among the top regulated transcripts. We then 
performed a Gene Set Enrichment Analysis (GSEA) of the significantly differentially regulated 
genes using the published gene expression profiles of p53 targets with gene sets of the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Supplementary Data S4) [23]. Consistent with the 
IPA analysis, GSEA demonstrated that the p53 signaling pathway was predominantly enriched 
among all 185 gene sets identified, with an enrichment score of 0.67 and a P value < 0.001(Figure 
4b).  
      
Figure 4 a) Significantly enriched target genes annotation in p53 by IPA. Targeting genes depicting the effect of 2 
(compared with DMSO) the expression pattern of p53 pathway target genes in the technical duplicates of whole 
transcriptome analysis (P < 0.05) regulated at least 1.8-fold. b) A Gene Set Enrichment Analysis (GSEA) was 
performed to assess whether genes that were differentially repressed by 2 were significantly associated with p53 
direct effectors expression profiles of KEGG gene sets and gene symbols (GSEA database 
c2.cp.kegg.v5.2.symbols.gmt). The enrichment score clearly showed that the genes at the top of the ranked 
list were overrepresented in the reference gene set. P < 0.001 and q < 0.001. 
 
A549 cells contain wild-type p53. Previous reports demonstrated that wild-type p53 plays a 
significant role in tumor inhibition. Stabilizing p53 and selectively activating p53 targets in p53 
wild-type cells resulted in a pronounced antiproliferative effect by inducing cell-cycle arrest and 
apoptosis[24]. One issue should be clarified here. As SAHA-I and CTB-I activated SOX2, OCT4, 
and NANOG in somatic human cells, while showing no antiproliferative activity, treatment with 2 
showed slight decreases of pluripotent genes after detail inspection of microarray data. Previous 
report demonstrated that downregulation of p53 pathway is required for efficient iPS cell 
reprogramming and maintenance[25]. To the contrast, the inhibition of pluripotent genes might 
result in p53 pathway activation based on the microarray data. Furthermore, 2 showed weak 
antitumor activity in p53-mutant SW620 cells. Therefore, these results combined with the cell 
viability assay and Microarray experiment discussed above led us to conclude that the antitumor 
activity caused by 2 in A549 cells was mainly attributable to the activation of p53 targeting genes. 
 
2.5 Apoptotic assay in the  A549 cell line 
Among the many roles of tumor suppressor p53, the role of p53-dependent apoptosis in 
pathological conditions was identified a long time ago, especially in cancer[24]. The microarray 
results led us to presume that p53-denpendent apoptosis might be the antitumor mechanism 
underlying the effects observed for 2. 
To confirm this hypothesis, cellular apoptosis was investigated via Annexin V-FITC assay, 
together with living cells and dead cells staining [26]. A549 cells were treated with 2 and 4 for 48 
h. Subsequently, apoptotic, necrotic, and healthy cells were stained with three different 
fluorophores (FITC-annexin V, ethidium homodimer III, and Hoechst 33342) (Figure 5).  
 
 
Figure 5. Effect of 2 and 4 on cellular apoptosis and necrotic activity. Representative images of apoptosis 
detection using fluorescence imaging. A549 cells were treated with DMSO, 2, and 4 at 2 µM for 48 s. A confocal 
image showed Hoechst 33342 staining, FITC-annexin V staining, ethidium homodimer III staining, and an overlay 
of the images. (scale bars represent 100 µm).  
 
In accordance with the IC50 of 2, 2 µM2 and 4 were applied to observe the process of cell death. In 
the control experiment (0.1% DMSO), apoptotic/dead cells were difficult to detect. Conversely, 
cultures treated with 2 showed more abundant apoptotic cells and an obvious subset of dead cells, 
which was consistent with the results of the cell viability assay described above. For 4, most of the 
cells were in a healthy condition, and only a few necrotic cells and apoptotic cells were detected. 
As wild-type p53 plays a major role in A549 cell apoptosis, these results suggested that 2 activated 
p53 downstream targets and induced cell apoptosis, leading to programmed cell death.  
 
3. Conclusions 
In addition to DNA mutation, heritable phenotypes, such as the inactivation of tumor suppressor 
genes, can also be acquired by epigenetic modifications, including DNA methylation and histone 
modifications [27]. Inactivation of tumor suppressors and their downstream pathways, such as the 
p53 pathway, or activation of proto-oncogenes and their correspondent pathways, such as the RAS 
pathway, have been studied widely and play pivotal roles in tumor initiation and development. 
Wild-type p53 plays a significant role in tumor inhibition. Stabilizing p53 and selectively 
activating the p53 pathway in p53 wild-type cells resulted in a pronounced antiproliferative effect 
via the induction of cell-cycle arrest and apoptosis [28]. In contrast, mutations in the p53 tumor 
suppressor gene are associated clinically with cancer stem cell progression and metastasis[29].  
In this study, we reported, for the first time, conjugates of DNA-binding domain and HAT 
inhibitors and evaluated their antitumor activity in A549 and SW620 cells. Among the C646-PIP 
derivatives identified, 2 (with a medium linker length of 13-atom) showed a potent antitumor 
activity with an IC50 of 1.8 µm in A549 cells. Moreover, with the help of Microarray analysis and 
an apoptosis assay, we demonstrated that the antitumor mechanism of 2 occurred via the 
activation of p53 target genes and triggered subsequent p53-dependent apoptosis. 
 
4. Experimental section 
4.1 General methods 
Reagents and solvents were purchased from standard suppliers and used without further 
purification. HAT inhibitor C646 was purchased from Sigma-aldrich (SML0002-25 mg). HPLC 
analysis were performed with a JASCO PU-2080 plus HPLC pump, a JASCO 807-IT HPLC 
UV/Vis detector, and a Chemcobond 5-ODS-H reversed-phase column (4.6×150 mm) in 0.1 % 
TFA in water using acetonitrile as the eluent at a flow rate of 1.0 mL min−1 under detection at 254 
nm. Electrospray ionization Time-of-flight mass spectrometry (ESI-TOF MS) was performed on a 
Bio-TOF II (Bruker Daltonics) mass spectrometer by using positive ionization mode. Machine-
assisted PIP syntheses were performed on a PSSM-8 (Shimadzu) system with computer-assisted 
operation on a 20 μmol scale using Fmoc chemistry.  
 
4.2 HAT inhibitor-PIP synthesis 
Machine-assisted automatic solid-phase synthesis of hairpin-type PIP was carried out with the 
use of a continuous-flow peptide synthesizer (PSSM-8, Shimadzu, Kyoto, Japan) at 0.1 mmol 
scale (100 mg of Fmoc oxime resin, 0.50 meq/g, Peptide Institute, Osaka, Japan) [15]. In a 
stepwise reaction, Fmoc-Py-COOH, Fmoc-Im-COOH, Fmoc-Py–Im-COOH, Fmoc-β-alanine-
COOH, 4-(Fmoc-amino) butyric acid and Fmoc-4,7-dioxanonanoic acid were coupled 
sequentially. Automatic solid-phase synthesis was started by washing with 
dimethylformamide (DMF); coupling with a monomer for 60 min in an environment of 1-
[bis(dimethylamino)methylene]- 5-chlorobenzotriazolium 3-oxide hexafluorophosphate 
(HCTU) and diisopropylethylamine (4 eq. each); removing the Fmoc group using 20% 
piperidine/DMF. We then isolated PIP after cleavage step (1 ml N,N-Dimethylpropylamine) 
for compound 1-4.  
Through 11-step solid phase synthesis and reverse-phase flash column, four PIPs were 
successfully synthesized. Then, our target compounds were synthesized and purified in high 
yield by conjugating commercially available C646 with 1-NH2, 2-NH2, 3-NH2 and 4-NH2 
respectively with the help of coupling agent PyBOP. To purify the PIP conjugates, high 
performance liquid chromatography (HPLC) was performed with use of a PU-980 HPLC 
pump, UV-975 HPLC UV/VIS detector (Jasco, Easton, MD), and Chemcobound 5-ODS-H 
column (Chemco Scientific, Osaka, Japan). 
PIP-I was obtained as a white powder. MS (ESI-TOF): m/z calcd for C57H71N21O102+ [M+2H]2+: 
604.7841; found: 6047302; HPLC: tR=16.09 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
40 min). 
1-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C61H77N23O112+ [M+2H]2+: 
654.8159; found: 654.6877; HPLC: tR=10.06 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
2-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C64H85N23O132+ [M+2H]2+: 
691.8343; found: 691.6911; HPLC: tR=10.11 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
3-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C67H91N23O152+ [M+2H]2+: 
728.8527; found: 728.7889; HPLC: tR=10.18 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
4-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C63H84N24O132+ [M+2H]2+: 
692.3320; found: 692.3352; HPLC: tR=9.692 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
1 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C85H96N26O162+ [M+2H]2+: 
868.3744; found: 868.2229; HPLC: tR=14.05 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
2 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C88H102N26O182+ [M+2H]2+: 
905.3927; found: 905.3164; HPLC: tR=14.10 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
3 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C91H108N26O202+ [M+2H]2+: 
942.4111; found: 942.4408; HPLC: tR=14.19 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
4 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C87H101N27O182+ [M+2H]2+: 
905.8904; found: 906.0553; HPLC: tR=13.83 min (0.1 % TFA/MeCN, linear gradient 0–100 %, 0–
20 min). 
Concentration determination: 410 nm.  C646-PIP concentrations were calibrated by 
comparing UV absorbance at 410 nm to C646. 
 
4.3 HAT activity assay in vitro 
HAT activity assays were determined using a commercial available kit (Biovision 
Biotechnology) according to the manufacturer’s instruction [11]. BioVision’s HAT Activity 
Assay Kit utilizes Acetyl CoA and H3 histone peptide as substrates, and recombinant p300 
core domain as the enzyme. In this assay, HAT enzyme catalyzes the transfer of acetyl groups 
from Acetyl-CoA to the histone peptide, thereby generating two products - acetylated peptide 
and CoA-SH. The CoA-SH reacts with the developer to generate a product that is detected 
fluorometrically at Ex/Em = 535/587 nm.  
 
4.4 Cell culture 
The base medium for A549 cell line is ATCC-formulated DMEM medium. To make the 
complete growth medium, we added the following components to the base medium for A549 
cells: fetal bovine serum (Sigma FBS) to a final concentration of 10% and L-glutamin to a 
final percentage of 2 mM.  SW620 cell line is supplemented with 1x penicillin/streptomycin. 
To make the complete growth medium, we added the following components to the base 
medium: FBS to a final concentration of 10% and penicillin/streptomycin to a final 
concentration of 1%. 
 
4.5 Cell proliferation assay 
A549 and SW620 cells were seeded on 96-well microplates (5×103 cells/well) in above 
mentioned media for 24 h at 37oC in 5% CO2. Then media was replenished with varying 
concentrations of conjugates C646-PIP for 96 h. Count Reagent SF (Nacalai Tesque) was 
added to each well to evaluate the cell proliferation. The absorbance of each well was 
measured at 450 nm by SpectraMax M2 (Molecular devices) microplate reader. 
 
4.6 Microarray analysis and data processing 
A549 cells were plated in 6-well plates at 2 × 105 cells/well and were treated for 48 hr with 
DMSO (0.01% control) and 1 μM concentration of PIP1, with technical duplicates in each 
condition respectively. Total RNA was prepared and the integrity of the RNA was checked 
using the Agilent 2100 Bioanalyzer (Agilent Technologies). One hundred nanograms of total 
RNA quantified by Nanodrop ND1000 v. 3.5.2 (Thermo Scientific) was labeled using a 
GeneChip WT PLUS Reagent kit (Affymetrix) and was hybridized to Human Gene 2.1 ST 
Array Strip (Affymetrix) for 20 ± 1 hr at 48°C. The hybridized arrays were washed, stained, 
and imaged on a GeneAtlas Personal Microarray System (Affymetrix). The hybridized probe 
set values were normalized using Affymetrix gene expression console software. Significant 
differentially expressed genes between the different conditions were analyzed using t test 
statistics (p<0.05). Microarray data reported here were deposited in the Gene Expression 
Omnibus database under the accession number (currently unavailable). 
Gene set enrichment analysis (GSEA) was conducted to detect statistically significant 2 
targeted genes associated with a gene set p53-regulated genes. Data were further analyzed by 
IPA (Ingenuity Systems; http://www.ingenuity.com) [23]. The IPA functional analysis was 
conducted to identify the significant biological functions associated with the microarray data 
set. Genes from the data sets that were regulated by ≥1.8-fold cutoff at p<0.05 were 
considered for the analysis. The p value was calculated using right-tailed Fisher’s exact test 
that defines the degree of association of the data set to the assigned biological function. 
 
4.7 Apoptosis Detection assay 
The apoptosis detection assay was performed using an Apoptotic, Necrotic, and Healthy Cells 
Detection Kit (Promokine) according to manufacturer’s instructions [26]. A549 cells were 
cultured in 8-well chamber slides at a density of 2×104 cells/well and treated with 2 μM PIP 
for 48 hr. Cells were washd with a binding buffer and stained with FITC-Annexin V, Ethidium 
Homodimer III, and Hoechst 33342; then they were subjected to fluorescence microscopy 
analysis (SpectraMax M2, Molecular Devices). 
 
4.8 Statistical analysis 
Results for continuous variables were presented as the mean ± standard error. Two-group 
differences in continuous variables were assessed by the unpaired T-test. P-values are two-
tailed with confidence intervals of 95%. Statistical analysis was performed by comparing 
treated samples with untreated controls.. 
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SW620 viability data 
 
Cell viability assay in SW620 cell line by WST-8 method. Cells were grown in media for 24 hs. 
Then media was replenished with varying concentrations of conjugates 2 and 4 (0.1, 1, 5 and 
10 μM) for 96 hs. Cell viability of SW620 was measured by WST-8 method. Each bar 






GSEA gene set information  
Gene testing dataset was downloaded from Gene set enrichment analysis (GSEA) 
database, named KEGG gene sets, gene symbols (c2.cp.kegg.v5.2.symbols.gmt). It 
contains 186 pathways and thousands of genes. The following table shows p53 
pathway genes. 
 
CASP9,CASP8, SFN, TSC2, IGF1, CDK1, GADD45B, RCHY1, ZMAT3, IGFBP3, 
RRM2B, BAI1, TP73, SERPINB5 RPRM, PPM1D, BID, MDM4, BAX, MDM2, 
TP53AIP1, CASP3, TP53I3, PMAIP1, PIDD RFWD2, PERP, GADD45G, EI24, 
SESN2, ATM, ATR, SESN3, CHEK2, APAF1, CDKN2A, RRM2, CDKN1A, BBC3, 
GADD45A, TNFRSF10B, DDB2, GTSE1, SIAH1, CCND1, CD82, PTEN, CDK2, 
CHEK1, SESN1, CDK4, SERPINE1, TP53, CCNE2 FAS, CDK6, CYCS, 
STEAP3, CCNB2, LOC651610, CCND2, SHISA5, CCNB1, CCNG1, CCNE1, 






ESI-MS data of whole compounds 
PIP-I was obtained as a white powder. MS (ESI-TOF): m/z calcd for C57H71N21O102+ 
[M+2H]2+: 604.7841; found: 604.7302; HPLC: tR=16.09 min (0.1 % TFA/MeCN, 
linear gradient 0–100 %, 0–40 min). 
 
 
1-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C61H77N23O112+ 
[M+2H]2+: 654.8159; found: 654.6877; HPLC: tR=10.06 min (0.1 % TFA/MeCN, 





2-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C64H85N23O132+ 
[M+2H]2+: 691.8343; found: 691.6911; HPLC: tR=10.11 min (0.1 % TFA/MeCN, 
linear gradient 0–100 %, 0–20 min). 
 
 
3-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C67H91N23O152+ 
[M+2H]2+: 728.8527; found: 728.7889; HPLC: tR=10.18 min (0.1 % TFA/MeCN, 





4-NH2 was obtained as a white powder. MS (ESI-TOF): m/z calcd for C63H84N24O132+ 
[M+2H]2+: 692.3320; found: 692.3352; HPLC: tR=9.692 min (0.1 % TFA/MeCN, 
linear gradient 0–100 %, 0–20 min). 
 
 
1 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C85H96N26O162+ 
[M+2H]2+: 868.3744; found: 868.2229; HPLC: tR=14.05 min (0.1 % TFA/MeCN, 





2 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C88H102N26O182+ 
[M+2H]2+: 905.3927; found: 905.3164; HPLC: tR=14.10 min (0.1 % TFA/MeCN, 
linear gradient 0–100 %, 0–20 min). 
 
 
3 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C91H108N26O202+ 
[M+2H]2+: 942.4111; found: 942.4408; HPLC: tR=14.19 min (0.1 % TFA/MeCN, 





4 was obtained as a red powder. MS (ESI-TOF): m/z calcd for C87H101N27O182+ 
[M+2H]2+: 905.8904; found: 906.8879; HPLC: tR=13.83 min (0.1 % TFA/MeCN, 
linear gradient 0–100 %, 0–20 min). 
 
 
